Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) Research & Development (2023 - 2025)

Camp4 Therapeutics' Research & Development history spans 3 years, with the latest figure at $8.4 million for Q4 2025.

  • For Q4 2025, Research & Development fell 16.4% year-over-year to $8.4 million; the TTM value through Dec 2025 reached $38.2 million, down 1.61%, while the annual FY2025 figure was $38.2 million, 1.58% down from the prior year.
  • Research & Development for Q4 2025 was $8.4 million at Camp4 Therapeutics, down from $9.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $10.3 million in Q2 2025 and bottomed at $8.4 million in Q4 2025.
  • The 3-year median for Research & Development is $9.7 million (2024), against an average of $9.6 million.
  • The largest YoY upside for Research & Development was 10.16% in 2025 against a maximum downside of 16.4% in 2025.
  • A 3-year view of Research & Development shows it stood at $9.8 million in 2023, then grew by 1.8% to $10.0 million in 2024, then fell by 16.4% to $8.4 million in 2025.
  • Per Business Quant, the three most recent readings for CAMP's Research & Development are $8.4 million (Q4 2025), $9.4 million (Q3 2025), and $10.3 million (Q2 2025).